Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Sep 29, 2016
Eisai Inc. announced today the presentation of seven abstracts featuring data on its cancer treatments at the European Society of Medical Oncology (ESMO) 2016 Congress. The abstracts highlight new...
-
Sep 29, 2016Eisai's CLEAR study will compare the company's multiple receptor TKI, lenvatinib, plus the anti-PD-1 pembrolizumab and lenvatinib plus the mTOR inhibitor everolimus versus sunitinib, the current standard of care in this setting
Eisai Inc. announced today the initiation of a multicenter, global, randomized Phase 3 study that will evaluate the efficacy and safety of two regimens containing Eisai's multiple receptor...
-
Sep 22, 2016METAvivor and Eisai Inc. Partner to Urge MBC Community to Discuss Living with Their Diagnosis, How They Draw Strength and Encouragement from Their Support Networks
"The cancer has spread. We can offer you treatment, but ultimately, it is incurable." A metastatic breast cancer (MBC) diagnosis comes with many medical, practical and emotional challenges as...
- Sep 21, 2016The Light of Life Foundation, ThyCa: Thyroid Cancer Survivors' Association, and Eisai Team Up to Increase Awareness by Urging People with Thyroid Cancer to Share their Experiences
A thyroid cancer diagnosis can lead to significant distress as patients and caregivers cope with various medical, emotional and economic challenges, as survivors, patients and caregivers have...
-
Sep 21, 2016
Eisai Inc. announced today the presentation of abstracts at the 86th Annual Meeting of the American Thyroid Association (ATA) that highlight an investigational Phase 2 trial currently recruiting...
